Replies to post #1819 on biomanbabasbiowave (BBBB$)

[~S.B.A.~]

$ARWR ran due to institutions not your post, but nice call on that.


Please re-read my post and you'll clearly see "you cannot find a better biotech at this current PPS range" . Key word is price-range. Now, let me explain myself since we have now clarified price range, and how $ABIO and $ARWR(Pre-Run) are at a difference of .7-1.00 and change.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89629564



Anyways, you cannot find a better biotech at $ABIO price range at this very current time. Founder of MYOGEN Dr. Bristow is the president of $ABIO. Back in 2006 he sold of Myogen, as you are aware for 2.6 billion to Gilead Sciences. Just recently Dr. Bristow brought on his old clinical development staff from Myogen to transition Gencaro into Phase 3 from 2b. Their current active partners are Medtronic and Lab corp. Just alone their partners who are gliding them through phase 2b have a collective market cap of 40bil. Gencaro is a therapy that is already proven to reduce A-fib in patience by 74%. Essentially, this company wants to replace metoprolol.

Easily see a buyout during phase 3 q1 fy '14 when the data is released, and or before.


Again, you cannot find a better biotech in this PPS range.

[~S.B.A.~]

pre-breakout screenshot